UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

(Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said ...

As Pfizer offers the British government promises to protect the UK research base in order to smooth its planned takeover of AstraZeneca ... that both research and development stay in Sweden ...

“Pharma continues turning to AI to better understand diseases and speed up drug discovery and development,” said Noam Solomon ...

Partex's platform will provide comprehensive analyses, including target identification, indication expansion, and molecular profiling, ultimately accelerating the process of bringing innovative ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors�reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

Last year, the two companies scaled back their agreement, leaving AstraZeneca with rights only in China and South Korea. FibroGen has been reeling since the Food and Drug Administration rejected its ...

AstraZeneca and Future Biogas today announced that the UK’s first unsubsidized biomethane plant dedicated to fuelling the life sciences sector is now operational. Located in Gonerby Moor, Lincolnshire ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

AstraZeneca PLC (NASDAQ:AZN – Free Report) – Investment analysts at Zacks Research dropped their ... focuses on the discovery, development, manufacture, and commercialization of prescription ...